IVIG Treatment Reported to Ease Pain in Sjögren Disease-Related Sensory Neuropathy
A new clinical report highlights a possible treatment option for nerve-related symptoms in selected patients.
Medscape listed a report on 2 November describing the use of intravenous immunoglobulin (IVIG) for pain associated with sensory neuropathy in Sjögren disease. The report suggests potential symptom relief, but detailed study information should be checked before drawing wider conclusions.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.
Sjögren disease is an autoimmune condition that commonly affects moisture-producing glands but can also involve other organs and systems. Some patients develop peripheral neuropathy, in which the nerves outside the brain and spinal cord become damaged or dysfunctional.
Sensory neuropathy may cause burning pain, tingling, numbness or abnormal sensitivity. These symptoms can interfere with sleep, mobility and daily activities. Treatment depends on the type of nerve involvement and the patient's overall condition.
Intravenous immunoglobulin is a treatment made from pooled antibodies and is used in selected immune-related disorders. The 2 November Medscape report highlights its use in pain associated with Sjögren disease-related sensory neuropathy. The accessible listing does not provide enough detail to confirm the number of patients, degree of benefit or long-term outcomes. IVIG is not a universal treatment for neuropathy and requires specialist assessment.
Story Photo Gallery
Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.